Clinical Trial Update: Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial SHARP evaluating hydroxychloroquine for at-risk population in COVID-19 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Tan Tock Seng Hospital | Conditions: Coronavirus Infection, Hydroxychloroquine Adverse Reaction | Phase 3 | Status: WITHDRAWN